{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:44:47Z","timestamp":1780735487984,"version":"3.54.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 69-year-old man with prostate cancer presented to the hospital with 2 weeks\u2019 history of fever, abdominal distension, and fatigue. Laboratory findings showed signs of acute liver failure, and marked elevation of lactate dehydrogenase and tumor marker levels. Abdominal CT showed hepatomegaly with multiple hypodense lesions in both lobes, suggesting metastases. FDG PET\/CT scan shows hypermetabolism unusually in the liver with significantly suppressed heart and brain activity, reminiscent of an FDG hepatic superscan. The hypermetabolic lesions confirmed with Tru-Cut needle biopsy of the liver as metastasis of prostate cancer.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003044","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T23:31:08Z","timestamp":1588635068000},"page":"474-476","source":"Crossref","is-referenced-by-count":7,"title":["FDG Hepatic Superscan Due to Metastatic Infiltration of Prostate Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Nilufer","family":"Yildirim","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem Sener","family":"Dede","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrak","family":"Gumuskaya","sequence":"additional","affiliation":[{"name":"Pathology, Ankara Yildirim Beyazit University, Affiliated Ankara City Hospital, Bilkent Integrated Health Campus, Cankaya, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/00003072-200410000-00005","article-title":"Unusually elevated liver radioactivity on F-18 FDG PET in Hodgkin\u2019s disease: hepatic \u201csuperscan.\u201d","volume":"29","year":"2004","journal-title":"Clin Nucl Med"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/RLU.0b013e3181b53f43","article-title":"FDG hepatic superscan caused by massive breast cancer invasion","volume":"34","year":"2009","journal-title":"Clin Nucl Med"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/RLU.0000000000000413","article-title":"18F-FDG hepatic superscan in a patient with chronic myeloid leukemia","volume":"39","year":"2014","journal-title":"Clin Nucl Med"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/1450-1147.167581","article-title":"Detection of diffuse infiltrative primary hepatic lymphoma on FDG PET-CT: hallmarks of hepatic superscan","volume":"15","year":"2016","journal-title":"World J Nucl Med"},{"key":"bib5-20230925","first-page":"179","article-title":"Unusual diffuse liver 18F-FDG uptake in melanoma patient treated by ipilimumab","volume":"20","year":"2017","journal-title":"Hell J Nucl Med"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/RLU.0000000000002134","article-title":"\u201cHepatic Superscan\u201d in a patient with hepatosplenic alphabeta T-cell lymphoma: 18F-FDG PET\/CT findings","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1097\/RLU.0000000000002211","article-title":"Diffuse liver metastasis from nasopharyngeal carcinoma found by 18F-FDG PET\/CT scans","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.semnuclmed.2016.07.004","article-title":"Is there use for FDG-PET in prostate cancer?","volume":"46","year":"2016","journal-title":"Semin Nucl Med"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.semnuclmed.2016.07.005","article-title":"PET tracers beyond FDG in prostate cancer","volume":"46","year":"2016","journal-title":"Semin Nucl Med"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/ijnm.IJNM_110_18","article-title":"A rare case of liver metastasis from prostate cancer mimicking hepatocellular carcinoma on immunohistochemistry: role of F-18 fluorodeoxyglucose positron emission tomography\/computed tomography in diagnosis","volume":"34","year":"2019","journal-title":"Indian J Nucl Med"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-05-0249","article-title":"2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy","volume":"11","year":"2005","journal-title":"Clin Cancer Res"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1634\/theoncologist.2017-0564","article-title":"Laboratory-based biomarkers and liver metastases in metastatic castration-resistant prostate Cancer","volume":"23","year":"2018","journal-title":"Oncologist"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clgc.2019.03.020","article-title":"Prognostic significance of sites of visceral metastatic disease in prostate cancer: a population-based study of 12,180 patients","volume":"17","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pros.23492","article-title":"The prognosis of different distant metastases pattern in prostate cancer: a population based retrospective study","volume":"78","year":"2018","journal-title":"Prostate"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:08:07Z","timestamp":1695622087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003044","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}